Published in Arch Pathol Lab Med on June 01, 2011
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell (2012) 4.16
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology (2011) 2.33
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer. Dig Dis Sci (2013) 1.43
Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med (2015) 1.35
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32
WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene (2013) 1.03
Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res (2012) 1.02
IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. J Clin Invest (2014) 0.96
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol (2012) 0.95
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer (2013) 0.94
Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One (2014) 0.93
Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol (2014) 0.91
Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma. J Gastroenterol (2014) 0.89
Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer. Oncotarget (2016) 0.88
MSX2 in pancreatic tumor development and its clinical application for the diagnosis of pancreatic ductal adenocarcinoma. Front Physiol (2012) 0.87
A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One (2014) 0.84
Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol (2012) 0.84
Validation of a robust proteomic analysis carried out on formalin-fixed paraffin-embedded tissues of the pancreas obtained from mouse and human. Proteomics (2012) 0.83
Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One (2013) 0.83
Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front Physiol (2013) 0.82
Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Cancer Gene Ther (2014) 0.82
Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Arch Pathol Lab Med (2014) 0.81
Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PLoS One (2013) 0.81
Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) (2015) 0.80
Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. World J Gastroenterol (2012) 0.80
A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget (2016) 0.80
GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch (2015) 0.79
PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma. BMC Cancer (2016) 0.78
Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol (2013) 0.78
CRABP-II is a highly sensitive and specific diagnostic molecular marker for pancreatic ductal adenocarcinoma in distinguishing from benign pancreatic conditions. Hum Pathol (2014) 0.78
Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. BMC Cancer (2016) 0.78
Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma. BMC Cancer (2014) 0.78
GATA factors in endocrine neoplasia. Mol Cell Endocrinol (2015) 0.77
Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol (2016) 0.77
Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. Oncotarget (2016) 0.76
CT contrast enhancement correlates with pathological grade and microvessel density of pancreatic cancer tissues. Int J Clin Exp Pathol (2015) 0.76
Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol (2014) 0.75
Nutrients and the Pancreas: An Epigenetic Perspective. Nutrients (2017) 0.75
The incidental cystic pancreas mass: a practical approach. Cancer Imaging (2012) 0.75
Deciphering the role of hedgehog signaling in pancreatic cancer. J Biomed Res (2016) 0.75
Pathological and prognostic role of mdig in pancreatic cancer. Genes Cancer (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Identification and characterization of the familial adenomatous polyposis coli gene. Cell (1991) 14.46
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer (2003) 8.35
Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet (1996) 7.94
Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet (1998) 7.52
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A (1993) 6.79
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer (2007) 6.57
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology (2000) 5.40
MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer (2006) 5.37
Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol (1988) 5.24
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet (1998) 4.96
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev (1995) 4.87
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A (1997) 4.38
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst (1997) 4.23
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev (1995) 4.19
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55
The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res (1983) 3.51
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 2.86
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med (2004) 2.67
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet (2005) 2.65
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology (1996) 2.59
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
The genetics of hereditary colon cancer. Genes Dev (2007) 2.58
The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res (2007) 2.54
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res (2000) 2.40
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther (2008) 2.38
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer (1998) 2.31
Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31
DNA methylation regulates MicroRNA expression. Cancer Biol Ther (2007) 2.21
Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol (2007) 2.16
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog (1998) 2.06
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther (2009) 2.01
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res (1998) 1.97
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
Familial pancreatic cancer. Arch Pathol Lab Med (2009) 1.93
Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res (2003) 1.90
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut (1993) 1.85
Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res (2008) 1.82
Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol (1999) 1.82
Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol (2000) 1.81
Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol (1993) 1.80
Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res (2004) 1.80
Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther (2002) 1.79
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol (2002) 1.75
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res (2005) 1.74
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol (2008) 4.70
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol (2007) 2.87
Focus on pancreas cancer. Cancer Cell (2002) 2.82
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther (2008) 2.38
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell (2007) 2.36
Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res (2003) 2.35
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther (2010) 2.33
Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol (2002) 2.33
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32